INGN-111

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameINGN-111
Drug Alias NameRV-AS-K-RAS (Introgen)gene therapy (Rhone-Polenc Rorer)gene therapy (Introgen/RPR)antisense (K-ras) (Introgen/RPR)INGN-111
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionOncogene proteins inhibitorsGTPase Ras inhibitors
TargetsOncogene proteinsGTPase Ras
Therapy Area/IndicationsLung NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIntrogen Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCentelion SASIntrogen Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsLung NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A